<?xml version='1.0' encoding='utf-8'?>
<document id="31519141"><sentence text="Use of Prescribed Psychotropic Medications in an Opioid Substitution Therapy Cohort." /><sentence text="Objective: Comorbid mental illness is extremely common in individuals receiving opioid substitution therapy"><entity charOffset="80-86" id="DDI-PubMed.31519141.s2.e0" text="opioid" /></sentence><sentence text=" The use of common psychiatric medications is complex in this cohort with increased risks of drug-drug interaction, overdose, and diversion or abuse of prescribed medication" /><sentence text=" We have therefore investigated rates of co-prescribing and psychiatric comorbidity in a cohort of individuals receiving therapeutic methadone or buprenorphine"><entity charOffset="133-142" id="DDI-PubMed.31519141.s4.e0" text="methadone" /><entity charOffset="146-159" id="DDI-PubMed.31519141.s4.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.31519141.s4.e0" e2="DDI-PubMed.31519141.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31519141.s4.e0" e2="DDI-PubMed.31519141.s4.e1" /></sentence><sentence text=" Methods: Comprehensive electronic medical records were accessed for a cohort of individuals (n = 698) receiving opioid substitution therapy at a single center in London, United Kingdom"><entity charOffset="113-119" id="DDI-PubMed.31519141.s5.e0" text="opioid" /></sentence><sentence text=" The following was collected for each individual: demographic data, current prescribed medications (including opioid substitution therapy agents), duration of prescription, indication for each prescription, and psychiatric diagnoses"><entity charOffset="110-116" id="DDI-PubMed.31519141.s6.e0" text="opioid" /></sentence><sentence text=" Results: A total of 610 individuals were included in the final analysis" /><sentence text=" High rates of psychotropic co-prescribing were observed, with 36" /><sentence text="7% of individuals receiving a psychotropic medication in addition to their opioid substitution drug, including 35" /><sentence text="4% receiving an antidepressant, 9" /><sentence text="2% an antipsychotic, 8" /><sentence text="6% a benzodiazepine, and 4"><entity charOffset="5-19" id="DDI-PubMed.31519141.s12.e0" text="benzodiazepine" /></sentence><sentence text="5% a gabapentinoid, rates that are far in excess of the local population prescription frequency; 75"><entity charOffset="5-18" id="DDI-PubMed.31519141.s13.e0" text="gabapentinoid" /></sentence><sentence text="5% of antipsychotic prescriptions and 47" /><sentence text="7% of benzodiazepine prescriptions were for an unlicensed indication"><entity charOffset="6-20" id="DDI-PubMed.31519141.s15.e0" text="benzodiazepine" /></sentence><sentence text=" Conclusions: This highlights the need for evidence-based treatment of comorbid mental illness for individuals receiving opioid substitution therapy"><entity charOffset="121-127" id="DDI-PubMed.31519141.s16.e0" text="opioid" /></sentence><sentence text="" /></document>